In the 15 years since the U.S. Food and Drug Administration approved the first HPV vaccine, access to cervical cancer vaccines worldwide has been limited by supply and cost challenges and inhibited by the multi-dose nature of the vaccines. However, a recent study, led in part by several researchers from the University of Washington, determined the sufficiency of a single-dose HPV vaccine through a randomized controlled trial in Kenya. Cervical cancer is a widespread issue that kills one woman every…
Research finds single-dose HPV vaccine to be highly effective









